Introduction
============

Hepatitis B virus (HBV) infection affects about 2 billion people, of whom about 350 million display chronic hepatitis B, defined by presence of hepatitis B surface antigen (HBsAg) in the serum ([@b29-tcrm-4-797]). It is estimated that between 235,000 and 328,000 people die annually due to liver cirrhosis and hepatocellular carcinoma, respectively ([@b41-tcrm-4-797]).

Transaminases have for the longest time been the hallmark of liver disease, and patients with normal liver transaminases have been considered to have no significant liver disease. Accordingly, guidelines used to state indication for antiviral therapy only in the presence of elevated liver enzymes ([@b10-tcrm-4-797]; [@b31-tcrm-4-797]; [@b35-tcrm-4-797]). This has, however, been challenged, based on recent findings that high viral load seems more important than elevation of liver transaminases ([@b5-tcrm-4-797]; [@b22-tcrm-4-797]).

Furthermore, using an antiviral to reduce HBV viral load has been shown to ameliorate liver disease ([@b32-tcrm-4-797]), so that it is now recommended to start antiviral therapy, despite normal liver enzymes, when there are other sign of liver disease, such as advanced fibrosis or risk factors to develop hepatocellular carcinoma ([@b8-tcrm-4-797]).

There are two different ways to inhibit HBV replication, either by using immune modulators such as interferon, pegylated interferon ([@b37-tcrm-4-797]; [@b28-tcrm-4-797]) or thymosin alfa ([@b53-tcrm-4-797]), or with antivirals. Antivirals available at present can then be divided into the "lamivudine-like" (L-nucleosides) and the "adefovir-like" drugs. The "lamivudine-like" and "adefovir-like" drugs differ in their pattern of resistance mutations.

While the "lamivudine-like" antivirals (telbivudine, clevudine, emtricitabin, and even entecavir, though additional mutations are required for full resistance in the latter) share a mutations pattern at position M204 of the YMDD (Tyrosine-Methionine-Aspartate-Aspartate motif in the catalytic domain of the viral polymerase/reverse transcriptase) motif of the HBV-polymerase, the "adefovir-like" antivirals seem to remain fully active against those mutants ([@b52-tcrm-4-797]).

The currently licensed and soon to be licensed therapies show differences in achieving viral load below a detectability threshold of 300 to 1000 copies per ml, as indicated in [Figure 1](#f1-tcrm-4-797){ref-type="fig"}. Additionally, they differ in their selection for viral resistance, which has not yet been reported for interferon, but for all antivirals to different degree.

Nonresponse to interferon might be more based on the cellular than on the viral level, as has been demonstrated in case of HCV infection ([@b1-tcrm-4-797]). In contrast to interferon, resistance to antivirals can occur frequently, especially in case of insufficient response ([@b18-tcrm-4-797]). Resistance after one year ranges from below 1% in adefovir ([@b15-tcrm-4-797]; [@b36-tcrm-4-797]) and entecavir ([@b4-tcrm-4-797]; [@b26-tcrm-4-797]) to about 32% in lamivudine-treated patients ([@b12-tcrm-4-797]). Long term data on resistance are scarce. There are no real controlled data for lamivudine, but it is generally presumed to rise to about 70% over 5 years. Likewise, it has been shown that resistance to adefovir emerges with a constant increase from 0%, 3%, 9%, and 18% to 29% within 1, 2, 3, 4, and 5 years, respectively, in HBeAg-negative patients years ([@b17-tcrm-4-797]). In addition, one must be aware that the chance of developing resistance is higher in HBeAg-positive vs. HBeAg-negative patients ([Table 1](#t1-tcrm-4-797){ref-type="table"}) ([@b18-tcrm-4-797]). For telbivudine reliable 1 and 2 year data are available, while data for entecavir only included subgroups of their patients ([@b7-tcrm-4-797]), thus making final conclusions difficult. The risk for entecavir resistance is significantly increased with underlying lamivudine resistance ([@b7-tcrm-4-797]).

Adefovir
========

When adefovir was initially developed for HIV therapy, its development was halted due to nephrotoxicity at the doses of 60 and 120 mg, which would have been required for HIV therapy ([@b25-tcrm-4-797]). Because of its anti-HBV-activity, adefovir was still further evaluated for treatment of HBV, where a 10 mg dose was shown to be sufficient to suppress HBV to similar levels as lamivudine, while in that dose there was no significant nephrotoxicity or other toxicity ([@b23-tcrm-4-797]).

A clear strength of the adefovir-like nucleosides is their higher genetic barrier to resistance. Though there are no "head to head" studies, adefovir in the licensed 10 mg dose is at least not more efficient than lamivudine, given in 100 mg. Still the resistance rate is much lower for adefovir, with "zero" after one year ([@b15-tcrm-4-797]; [@b36-tcrm-4-797]). However, it has been noted that resistance to adefovir develops more frequently in the presence of underlying lamivudine resistance, if lamivudine is not continued ([@b51-tcrm-4-797]).

Furthermore, it has been demonstrated that the 30 mg dose of adefovir would be superior than the 10 mg concerning antiviral efficacy ([@b36-tcrm-4-797]), which was recently reinforced by a study using 20 mg daily in 5 lamivudine-resistant patients with insufficient response to the 10 mg adefovir dose ([@b21-tcrm-4-797]). Thus, a higher dose of adefovir would be desired, but the 30 mg dose was shown to lead to a significantly more frequent increase in creatinine levels than the 10 mg dose ([@b36-tcrm-4-797]).

The viral load reduction achieved by lamivudine is no longer the standard, but instead the viral load reduction achieved by entecevair and telbivudine is preferred, both leading to more than 6 log viral load reduction ([@b4-tcrm-4-797]; [@b18-tcrm-4-797]). As a result, it would be more beneficial to utilise adefovir-like drugs, with both higher antiviral activity and lower toxicities. Adefovir-like drugs are currently pradefovir (also known as remofovir; almefovir; Hepavir B™) ([@b47-tcrm-4-797]), which is a prodrug of adefovir, tenofovir, LB-80380 (also known as ANA 380) and alamifovir (also known as MCC-478) ([@b3-tcrm-4-797]).

Pradefovir, a liver-targeted adefovir
=====================================

Based on the concept of increased levels of adefovir at the main target organ, the liver, with low systemic exposure, pradefovir was developed. Pradefovir (also known as remofovir; almefovir; Hepavir B) is based on adefovir and a specific side chain making it into an inert drug, until activation through cytochrome p450 (CYP3A4). As this compound is abundant in the liver but scarce elsewhere in the body ([@b2-tcrm-4-797]), it is almost exclusively activated in the liver, thereby high drug levels are achieved in the liver, while the systemic exposure has been shown to be low ([@b34-tcrm-4-797]).

Dependence on CYP3A4, however, makes pradefovir prone to interaction with other drugs that also require, induce or inhibit CYP3A4. In line with the need for further metabolization, the AUC variation was higher on prade-fovir compared to adefovir ([@b30-tcrm-4-797]). The antiviral activity in that phase II study was more pronounced on pradefovir doses of 10 mg and higher. The open-label phase II trials compared pradefovir (5, 10, 20, or 30 mg) with 10 mg adefovir in chronically HBV-infected patients, who were treated for 24 to 48 weeks ([@b30-tcrm-4-797], [@b33-tcrm-4-797]) This study included 47, 49, 48, 48, and 50 patients into the pradefovir 5, 10, 20 and 30 mg arm and the 10 mg adefovir arm respectively. After 24 and 48 weeks, a viral reduction was described to be 3.39, 4.22, 4.33, and 5.02 log copies per ml for the pradefovir mesylate dose of 5, 10, 20, and 30 mg, respectively, compared with 3.66 with 10 mg adefovir dipivoxil after 24 weeks ([@b30-tcrm-4-797]) and 4.09, 4.84, 4.89, 5.54 log copies per ml for the pradefovir mesylate dose of 5, 10, 20, and 30 mg, respectively, compared to 4.19 on 10 mg adefovir dipivoxil after 48 weeks ([@b33-tcrm-4-797]). However, pradefovir was recently put on hold concerning its further development based on increased tumor incidence in animal studies ([@b47-tcrm-4-797]). At present, it is unclear whether this is a class effect of "adefovir-like" substances, the high doses of adefovir in the liver, or related to the prodrug delivery used here.

Tenofovir
=========

Tenofovir as adefovir was developed for HIV therapy and has proven to have lower renal toxicity and good activity, actually making it currently one of the top nucleoside reverse transcriptase inhibitor backbones in therapies for HIV ([@b9-tcrm-4-797]). Nonetheless, renal toxicity is still a concern in relation to tenofovir, though not quite proven to be causally associated ([@b43-tcrm-4-797]). It has been demonstrated in some case series that tenofovir, at least in the dose of 245 mg tenofovir dipivoxil equivalent to 300 mg tenofovir dipivoxil fumarate equivalent to 136 mg tenofovir as given for HIV, is superior to the 10 mg dose of adefovir ([@b49-tcrm-4-797]), which has been reinforced by reactivation after switching from tenofovir to adefovir ([@b48-tcrm-4-797]; [@b11-tcrm-4-797]) and improved suppression after switching from adefovir to tenofovir ([@b50-tcrm-4-797]). A trend towards better response has also been seen in a placebo controlled trial of HIV infected patients ([@b42-tcrm-4-797]).

There are two controlled trials currently underway comparing tenofovir to adefovir, which have only been presented as press releases ([@b13-tcrm-4-797], [@b14-tcrm-4-797]) and abstract form. The one year data have been presented at the 2007 AASLD (American Association for the Study of the Liver) annual meeting. According to these press releases and the presentations ([@b19-tcrm-4-797]; [@b38-tcrm-4-797]), Tenofovir is significantly more potent than adefovir. Tenofovir achieved the highest rates in undetectability of HBV-DNA observed in any drug trial related to hepatitis B. However, the comparison to the other currently marketed drug is difficult given that the viral load of the enrolled patients was in average about 1 log lower than in the other trials. It might well be that the antiviral efficacy is superior to that of the other currently marketed drugs. However, to finally asses this, a head to head study would be required, but unlikely to take place. However, in addition to its efficacy, no emergence of viral breakthrough has been observed on tenofovir. In addition, HBsAg loss, otherwise mostly only seen in relation to interferon-based therapies has been observed in about 3% after 48 weeks and 4% of tenofovir-treated patients after 69 weeks of therapy ([@b20-tcrm-4-797]). However, no loss of HBsAg has been observed in HBeAg-negative patients on tenofovir.

After tenofovir's licensure for HBV therapy, it is probable that adefovir's only indication will be the HIV-positive patient needing HBV-treatment, but not yet requiring anti-HIV therapy ([@b46-tcrm-4-797]).

A mutation, rtA194T, has been reported to emerge on tenofovir ([@b44-tcrm-4-797]), but it did not lead to a real viral load increase, thus awaiting further confirmation.

Alamifovir
==========

Alamifovir, also known as MCC-478 or LY582563, is a adenosine nucleotide analogue, which has activity against both HIV and HBV. In a phase I study 66 HBV-DNA positive patients were randomized to alamifovir or placebo in a 3:1 ratio within each of 7 dosing groups: 2.5 mg BID, 5 mg BID, 10 mg BID, 2.5 mg QD, 5 mg QD, 10 mg QD, and 20 mg QD. That study showed no difference between once daily and twice daily dosing ([Table 2](#t2-tcrm-4-797){ref-type="table"}). In this small study, there were also no significant differences between the groups except towards placebo. At present, no new data have been presented within the last two years.

LB-80380
========

LB-80380 is also known as ANA 380, and is a 9-\[1-(Ph osphonomethoxycyclopropyl) methyl\] guanine (PMCG). Even though it is frequently regarded as a "adefovir-like" nucleotide, it is considered, at least by some, as a representative of a novel class of phosphonate nucleosides that blocks HBV replication with an excellent potency (EC~50~ of 0.5 μM) in HepG2 2.2.15 cells ([@b6-tcrm-4-797]). LB-80380 did not show any cytotoxicity in several human cell lines in concentrations up to 2000 times of that required for an EC50 for HBV inhibition. It seems not to inhibit HIV replication, at least at 30 μM, which is 60 times the dose required for HBV. This, however, requires further evaluation in light of the unexpected activity of entecavir against HIV ([@b40-tcrm-4-797]). Furthermore, in its oral form, PMCDG dipivoxil, excellent efficacy was achieved in HBV infected woodchucks at 5 mg/kg/d ([@b6-tcrm-4-797]).

In vivo LB-80380 has been also tested in naïve and lamivudine refractory patients ([@b54-tcrm-4-797]). When doses of 30, 60, 120, and 240 mg were given once daily for 4 weeks, a mean maximum viral load reduction of 3.05, 4.20, 3.67, and 3.68 log10 copies/ml was achieved for the 30, 60, 120, and 240 mg doses, respectively, in naïve patients ([@b54-tcrm-4-797]). Slightly lower reduction was achieved in lamivudine refractory patients with 2.1, 2.5, 2.6, 3.0, and 3.0 log10 as well as 2.8, 3.2, 3.9, and 3.7 log10 after 4 and 12 weeks, respectively in the 30, 60, 90, 150, and 240 mg dose groups ([@b27-tcrm-4-797]).

Conclusions
===========

In summary, the "adefovir-like" drugs best used in practice are adefovir in the HIV-infected patient in need of anti-HBV therapy, while not yet needing anti-HIV therapy ([@b46-tcrm-4-797]). In all other patients, I would presume teno-fovir to take over, where adefovir is currently used given its lower toxicity and higher activity. Whether any of the other "adefovir-like" drugs will make it to the market remains to be seen. It is probable that all could be well combined with lamivudine, which will soon be off-patent. Thus, it might be a cheap but potentially very active addition to any "adefovir-like" drug, given their different resistance profile. However, in the case of tenofovir, this is not required, given its existence in combination with the lamivudine-like drug emtricitabine.
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###### 

Resistance defined by 1 log viral load increase over nadir after one and two years within the GLOBE trial

  Rate of resistance   Lamivudine       Telbivudine                       
  -------------------- ---------------- ---------------- ---------------- ----------------
                       HBeAg-positive   HBeAg-negative   HBeAg-positive   HBeAg-negative
  Year 1               8.2              3.0              8.5              2.1
  Year 2               35.0             21,6             21.6             8.6

Adapted from [@b18-tcrm-4-797].

###### 

Viral load reduction on alamifovir

  Parameter              *N*         Placebo   2.5 mg/d   5 mg/d   10 mg/d   20 mg/d                 
  ---------------------- ----------- --------- ---------- -------- --------- --------- ------ ------ ------
  Log-change on day 29   Mean drop   0,064     1,52       2,02     1,96      1,98      2,49   2,53   2,50
